ARQT Key Statistics, Chart & Performance
The current stock price of ARQT is 25.57 USD. In the past month the price decreased by -11.83%. In the past year, price increased by 120.24%.
ARQT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ARQT. When comparing the yearly performance of all stocks, ARQT is one of the better performing stocks in the market, outperforming 94.38% of all stocks.
ARQT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARQT. The financial health of ARQT is average, but there are quite some concerns on its profitability.
ARQT Financial Highlights
Over the last trailing twelve months ARQT reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 79.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.95% | ||
| ROE | -28.04% | ||
| Debt/Equity | 0.68 |
ARQT Forecast & Estimates
14 analysts have analysed ARQT and the average price target is 32.26 USD. This implies a price increase of 26.15% is expected in the next year compared to the current price of 25.57.
For the next year, analysts expect an EPS growth of 82.5% and a revenue growth 93.08% for ARQT
ARQT Ownership
ARQT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.79B | ||
| AMGN | AMGEN INC | 15.76 | 185.60B | ||
| GILD | GILEAD SCIENCES INC | 17.45 | 177.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.19 | 119.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 664.92 | 44.80B | ||
| INSM | INSMED INC | N/A | 32.84B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.7 | 26.27B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.45B | ||
| INCY | INCYTE CORP | 15.99 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About ARQT
Company Profile
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 342 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Company Info
ARCUTIS BIOTHERAPEUTICS INC
3027 Townsgate Road, Suite 300
Westlake Village CALIFORNIA 91361 US
CEO: Todd Franklin Watanabe
Employees: 342
Phone: 18054185006
ARCUTIS BIOTHERAPEUTICS INC / ARQT FAQ
What does ARCUTIS BIOTHERAPEUTICS INC do?
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 342 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
What is the current price of ARQT stock?
The current stock price of ARQT is 25.57 USD. The price increased by 0.79% in the last trading session.
Does ARQT stock pay dividends?
ARQT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARQT stock?
ARQT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is ARCUTIS BIOTHERAPEUTICS INC (ARQT) expected to grow?
The Revenue of ARCUTIS BIOTHERAPEUTICS INC (ARQT) is expected to grow by 93.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ARQT stock?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) will report earnings on 2026-02-25, after the market close.